<table>
<thead>
<tr>
<th>March 2</th>
<th></th>
<th><strong>Program Schedule</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 – 8:15</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>8:15 – 8:30</td>
<td>Welcome and Program Overview/ Pre-test</td>
<td></td>
</tr>
</tbody>
</table>
| 8:30 – 9:00    | Epidemiology of Tuberculosis – Andrea Cote, D.V.M., M.P.H., Wyoming Department of Health  
|                | • Describe the TB epidemic in terms of susceptible groups  
|                | • Describe major factors that will affect future trends in TB |                                                        |
| 9:00 – 10:00   | TB Transmission and Infection Control – Shu Ha Wang, M.D., Ohio State University  
|                | • Describe the pathogenesis of *M. tuberculosis*  
|                | • Explain how drug-resistant TB disease develops |                                                        |
| 10:00 – 10:15  | **Break**                        |                                                        |
| 10:15 – 10:45  | Diagnosis of LTBI – Stacey A. Rizza, M.D., Mayo Clinic Center for Tuberculosis  
|                | • Explain Use of TST  
|                | • Explain use of IGRA testing |                                                        |
| 10:45 – 11:45  | Radiology – Seth Iverson, M.D., Casper Medical Imaging and Outpatient Radiology  
|                | • Identify the major structures on a normal chest x-ray  
|                | • Identify major chest x-ray abnormalities commonly seen in TB |                                                        |
| 11:45 – 1:00   | **Lunch**                        |                                                        |
| 1:00 – 1:30    | LTBI Treatment – Stacey A. Rizza, M.D., Mayo Clinic Center for Tuberculosis  
|                | • Describe the current guidelines for LTBI treatment  
|                | • Describe monitoring recommendations for patients on LTBI treatment |                                                        |
| 1:30 – 2:30    | Treatment of TB and Drug Resistance of TB – Shu Ha Wang, M.D., Ohio State University  
|                | • Identify the basic principles of drug resistant TB  
|                | • Describe the current guidelines for the treatment of TB disease including the newly released CDC guidelines |                                                        |
| 2:30 – 2:45    | **Break**                        |                                                        |
| 2:45 – 3:45    | Adverse Drug Reactions – Stacey A. Rizza, M.D., Mayo Clinic Center for Tuberculosis  
|                | • Describe the common adverse reactions to TB treatment regimens  
|                | • Explain how to manage adverse reactions to TB treatment regimens |                                                        |
| 3:45 – 4:15    | Clinical Case Discussion #1 – LTBI Case Presentation – Samantha Birch, M.P.H., Wyoming Department of Health  
|                | • Indicate transfer of knowledge of tuberculosis testing, diagnosis, and treatment to a clinical case |                                                        |
| 4:15 – 4:30    | Q&A / Post-test                  |                                                        |
## March 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45-8:00</td>
<td>Sign in</td>
<td></td>
</tr>
<tr>
<td>8:00 – 8:15</td>
<td>Review / Q&amp;A/ Pre- test</td>
<td></td>
</tr>
<tr>
<td>8:15 – 9:15</td>
<td>TB and Pediatrics – W. Garrett Hunt, M.D., Nationwide Children’s Hospital</td>
<td>Describe the epidemiology of pediatric TB in the US</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Describe the clinical presentation of TB in children</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Describe treatment regimens for pediatric LTBI and active TB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Review the guidelines for healthcare facility TB programs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Summarize recommendations for healthcare facilities</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:30 – 11:15</td>
<td>Immigration and Class B Arrivals – Alicia Earnest, M.P.H., Minnesota Department of Health</td>
<td>Describe the strengths and weaknesses of the available methods for screening for tuberculosis in immigrants and refugees</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recognize the epidemiology of tuberculosis among immigrants to the US</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Review problems with drug resistance around the world</td>
</tr>
<tr>
<td>11:15 – 12:00</td>
<td>Clinical Case Discussion #2 - Pediatric Cases – Vivian Watson, R.N., Wyoming Department of Health</td>
<td>Indicate transfer of knowledge of tuberculosis testing, diagnosis, and treatment to a clinical case.</td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td>Wyoming Patient and Provider Resources – Brittany Wardle, M.P.H., Wyoming Department of Health</td>
<td>Provider resources</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient resources</td>
</tr>
<tr>
<td>12:15 – 12:30</td>
<td>Resource Review and Final Q&amp;A/ Post- test – Cindy Hafferty, Mayo Clinic Center for Tuberculosis</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>